Skip to main content
. 2015 Dec 7;10(12):e0144538. doi: 10.1371/journal.pone.0144538

Fig 3. Overall analysis of disability progression in placebo-control randomized clinical trials of different disease modifying therapies in patients with relapsing-remitting multiple sclerosis.

Fig 3